StockNews.AI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aquestive Therapeutics, Inc. - AQST

StockNews.AI • 21 hours

AQSTVRTXNTRP
High Materiality9/10

Information

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...

Original source

AI Summary

Pomerantz LLP is investigating Aquestive Therapeutics for potential securities fraud amid FDA deficiencies in the Anaphylm NDA, causing a 37% stock price drop. This ongoing scrutiny could result in legal ramifications, impacting investor sentiment and share performance significantly.

Sentiment Rationale

The investigation and significant stock drop indicate severe market distrust, reminiscent of past cases where investigations led to prolonged stock underperformance, such as Valeant Pharmaceuticals during its scandals.

Trading Thesis

Consider selling or avoiding AQST due to legal risks and declining market confidence.

Market-Moving

  • Ongoing investigation into AQST may exacerbate investor concerns and depress stock price.
  • FDA’s NDA deficiencies signal a prolonged approval process, risking future revenues.
  • Class action lawsuits can create significant legal and financial liabilities for AQST.
  • A 37% price drop reflects severe market reaction, indicating potential volatility.

Key Facts

  • Pomerantz LLP is investigating claims against Aquestive Therapeutics.
  • Inquiry involves potential securities fraud or unlawful practices by company officials.
  • On January 9, 2026, FDA identified deficiencies in Anaphylm's NDA review.
  • Company’s stock fell 37.04% to $3.91 due to FDA notification.
  • Investors are encouraged to contact Pomerantz for class action information.

Companies Mentioned

  • Pomerantz LLP (N/A): A premier firm involved in class action litigation against AQST.
  • FDA (N/A): Identified key deficiencies in AQST's NDA, impacting approval timeline.

Corporate Developments

The ongoing legal investigation concerning AQST fits the 'Corporate Developments' category, as it involves potential misconduct that could affect the company's reputation and operational viability.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims for Investors of Aquestive Therapeutics, Inc. (AQST)

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is currently investigating potential claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). This investigation focuses on whether Aquestive and key officers or directors may have engaged in securities fraud or other unlawful business practices that could impact investors.

Details of the Investigation

Investors are encouraged to reach out to Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 7980 for further information.

On January 9, 2026, the President and CEO of Aquestive announced that the FDA had identified deficiencies within the Company's New Drug Application (NDA) for Anaphylm. This notification has raised concerns as it precludes discussing labeling and post-marketing commitments at this time. Notably, the FDA did not specify the deficiencies discovered.

Impact on AQST Stock

In response to this announcement, Aquestive’s stock experienced a significant decline, falling by $2.30 per share or 37.04%, closing at $3.91 per share on January 9, 2026. This decline signals potential investor concerns regarding the company’s future and compliance with regulatory standards.

About Pomerantz LLP

Pomerantz LLP, which has offices in major locations including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as a leader in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, a pioneer in the class action field, the firm has a long-standing tradition of advocating for victims of securities fraud and corporate misconduct.

Over the past 85 years, Pomerantz LLP has successfully recovered multimillion-dollar damages on behalf of its clients. For more information, visit www.pomlaw.com.

Contact Information

For inquiries related to this investigation and the potential claims against Aquestive Therapeutics, Inc., contact:

This constitutes attorney advertising. Previous results do not guarantee similar outcomes for future cases.

Related News